12:29 AM GMT, Oct 25, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Regeneron gains on 3Q12 results, Eylea guidance
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $9.70 to $162.69 on Wednesday after reporting the third full quarter
Read the full 162 word article